Press Release: Osimertinib Efficacy Against Intracranial EGFRvIII-Positive GBMs

The Glioblastoma Drug Discovery Group announces that osimertinib¬†significantly prolongs the survival of immunocompromised mice bearing intracranial EGFRvIII-positive glioblastoma! These data warrant the commencement of studies designed to test osimertinib’s safety and efficacy in GBM patients.

One Comment

"coin press"

magnificent submit, very informative. I ponder why the other experts of this sector don’t understand this.
You must proceed your writing. I am confident, you have a huge
readers’ base already!

Reply

Leave a Reply

Your email address will not be published. Required fields are marked *